Efficacy and safety of antiviral treatment for COVID-19 from evidence in studies of SARSCoV-2 and other acute viral infections: a systematic review and meta-analysis.
Efficacy and safety of antiviral treatment for COVID-19 from evidence in studies of SARSCoV-2 and other acute viral infections: a systematic review and meta-analysis.
CMAJ. 2020 Jun 03;:
Authors: Liu W, Zhou P, Chen K, Ye Z, Liu F, Li X, He N, Wu Z, Zhang Q, Gong X, Tang Q, Du X, Ying Y, Xu X, Zhang Y, Liu J, Li Y, Shen N, Couban RJ, Ibrahim QI, Guyatt G, Zhai S
Abstract
BACKGROUND: Antiviral medications are being given empirically to some patients with coronavirus disease 2019 (COVID-19). To support the development of a COVID-19 management guideline, we conducted a systematic review that addressed the benefits and harms of 7 antiviral treatments for COVID-19.
METHODS: We searched MEDLINE, Embase, Cochrane Central Register of Controlled Trials (CENTRAL), PubMed and 3 Chinese databases (CNKI, WANFANG and SinoMed) through Apr. 19, medRxiv and Chinaxiv through Apr. 27, and Chongqing VIP through Apr. 30, 2020. We included studies of ribavirin, chloroquine, hydroxychloroquine, umifenovir (arbidol), favipravir, interferon and lopinavir/ritonavir. If direct evidence from COVID-19 studies was not available, we included indirect evidence from studies of severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) for efficacy outcomes and other acute respiratory viral infections for safety outcomes.
RESULTS: In patients with nonsevere COVID-19 illness, the death rate was extremely low, precluding an imp...
Source: Canadian Medical Association Journal - Category: General Medicine Tags: CMAJ Source Type: research
More News: Canada Health | China Health | Coronavirus | COVID-19 | Databases & Libraries | General Medicine | Hospitals | Hydroxychloroquine | Intensive Care | Kaletra | MERS | Middle East Health | Norvir | Respiratory Medicine | SARS | Study